Cargando…
Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization
Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vasc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221810/ https://www.ncbi.nlm.nih.gov/pubmed/28115846 http://dx.doi.org/10.2147/IJN.S114754 |
_version_ | 1782492885085585408 |
---|---|
author | Chang, Che-Yi Wang, Ming-Chen Miyagawa, Takuya Chen, Zhi-Yu Lin, Feng-Huei Chen, Ko-Hua Liu, Guei-Sheung Tseng, Ching-Li |
author_facet | Chang, Che-Yi Wang, Ming-Chen Miyagawa, Takuya Chen, Zhi-Yu Lin, Feng-Huei Chen, Ko-Hua Liu, Guei-Sheung Tseng, Ching-Li |
author_sort | Chang, Che-Yi |
collection | PubMed |
description | Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vascular endothelial cells for corneal NV treatment. An arginine–glycine–aspartic acid (RGD) peptide–hyaluronic acid (HA)-conjugated complex coating on the gelatin/EGCG self-assembly nanoparticles (GEH-RGD NPs) was synthesized for targeting the α(v)β(3) integrin on human umbilical vein endothelial cells (HUVECs) in this study, and a corneal NV mouse model was used to evaluate the therapeutic effect of this nanomedicine used as eyedrops. HA-RGD conjugation via COOH and amine groups was confirmed by (1)H-nuclear magnetic resonance and Fourier-transform infrared spectroscopy. The average diameter of GEH-RGD NPs was 168.87±22.5 nm with positive charge (19.7±2 mV), with an EGCG-loading efficiency up to 95%. Images of GEH-RGD NPs acquired from transmission electron microscopy showed a spherical shape and shell structure of about 200 nm. A slow-release pattern was observed in the nanoformulation at about 30% after 30 hours. Surface plasmon resonance confirmed that GEH-RGD NPs specifically bound to the integrin α(v)β(3). In vitro cell-viability assay showed that GEH-RGD efficiently inhibited HUVEC proliferation at low EGCG concentrations (20 μg/mL) when compared with EGCG or non-RGD-modified NPs. Furthermore, GEH-RGD NPs significantly inhibited HUVEC migration down to 58%, lasting for 24 hours. In the corneal NV mouse model, fewer and thinner vessels were observed in the alkali-burned cornea after treatment with GEH-RGD NP eyedrops. Overall, this study indicates that GEH-RGD NPs were successfully developed and synthesized as an inhibitor of vascular endothelial cells with specific targeting capacity. Moreover, they can be used in eyedrops to inhibit angiogenesis in corneal NV mice. |
format | Online Article Text |
id | pubmed-5221810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-52218102017-01-23 Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization Chang, Che-Yi Wang, Ming-Chen Miyagawa, Takuya Chen, Zhi-Yu Lin, Feng-Huei Chen, Ko-Hua Liu, Guei-Sheung Tseng, Ching-Li Int J Nanomedicine Original Research Neovascularization (NV) of the cornea can disrupt visual function, causing ocular diseases, including blindness. Therefore, treatment of corneal NV has a high public health impact. Epigalloccatechin-3-gallate (EGCG), presenting antiangiogenesis effects, was chosen as an inhibitor to treat human vascular endothelial cells for corneal NV treatment. An arginine–glycine–aspartic acid (RGD) peptide–hyaluronic acid (HA)-conjugated complex coating on the gelatin/EGCG self-assembly nanoparticles (GEH-RGD NPs) was synthesized for targeting the α(v)β(3) integrin on human umbilical vein endothelial cells (HUVECs) in this study, and a corneal NV mouse model was used to evaluate the therapeutic effect of this nanomedicine used as eyedrops. HA-RGD conjugation via COOH and amine groups was confirmed by (1)H-nuclear magnetic resonance and Fourier-transform infrared spectroscopy. The average diameter of GEH-RGD NPs was 168.87±22.5 nm with positive charge (19.7±2 mV), with an EGCG-loading efficiency up to 95%. Images of GEH-RGD NPs acquired from transmission electron microscopy showed a spherical shape and shell structure of about 200 nm. A slow-release pattern was observed in the nanoformulation at about 30% after 30 hours. Surface plasmon resonance confirmed that GEH-RGD NPs specifically bound to the integrin α(v)β(3). In vitro cell-viability assay showed that GEH-RGD efficiently inhibited HUVEC proliferation at low EGCG concentrations (20 μg/mL) when compared with EGCG or non-RGD-modified NPs. Furthermore, GEH-RGD NPs significantly inhibited HUVEC migration down to 58%, lasting for 24 hours. In the corneal NV mouse model, fewer and thinner vessels were observed in the alkali-burned cornea after treatment with GEH-RGD NP eyedrops. Overall, this study indicates that GEH-RGD NPs were successfully developed and synthesized as an inhibitor of vascular endothelial cells with specific targeting capacity. Moreover, they can be used in eyedrops to inhibit angiogenesis in corneal NV mice. Dove Medical Press 2016-12-30 /pmc/articles/PMC5221810/ /pubmed/28115846 http://dx.doi.org/10.2147/IJN.S114754 Text en © 2017 Chang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Chang, Che-Yi Wang, Ming-Chen Miyagawa, Takuya Chen, Zhi-Yu Lin, Feng-Huei Chen, Ko-Hua Liu, Guei-Sheung Tseng, Ching-Li Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
title | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
title_full | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
title_fullStr | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
title_full_unstemmed | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
title_short | Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
title_sort | preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221810/ https://www.ncbi.nlm.nih.gov/pubmed/28115846 http://dx.doi.org/10.2147/IJN.S114754 |
work_keys_str_mv | AT changcheyi preparationofarginineglycineasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT wangmingchen preparationofarginineglycineasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT miyagawatakuya preparationofarginineglycineasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT chenzhiyu preparationofarginineglycineasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT linfenghuei preparationofarginineglycineasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT chenkohua preparationofarginineglycineasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT liugueisheung preparationofarginineglycineasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization AT tsengchingli preparationofarginineglycineasparticacidmodifiedbiopolymericnanoparticlescontainingepigalloccatechin3gallatefortargetingvascularendothelialcellstoinhibitcornealneovascularization |